Itolizumab

Introduction:

Itolizumab is Biocon's second breakthrough 'lab-to-market' anti-CD6 monoclonal antibody. It debuted in India in 2013, and since then, it’s been making a difference in treating severe psoriasis. This drug's journey has been long but exciting! Itolizumab’s dosage administration is pretty straightforward, but it has a minimal risk of side effects. Have you ever wondered how a single drug can impact many health conditions? Well, read below to learn more about it in detail.

What Are the Approved Uses of Itolizumab?

The Drug Controller General of India has recently approved Itolizumab for off-label use in treating cytokine release syndrome associated with COVID-19 infection. Biocon partnered with Equillium in 2017 to produce Itolizumab, primarily for autoimmune disorders (the immune system attacks the body). Itolizumab received FDA (U.S. Food and Drug Administration) approval for treating lupus nephritis (kidney inflammation caused by lupus) and acute graft-versus-host disease (a condition where transplanted cells attack the recipient's body).

Itolizumab shows promising results in shortening treatment times and improving outcomes. Additionally, it is conditionally approved for emergency use to manage cytokine release syndrome (an immune overreaction) in COVID-19 patients with moderate to severe respiratory distress. Studies show it significantly reduces mortality in these cases. But, have you considered the many different ways a drug can be approved and used? Itolizumab’s versatility is a good example.

What Is Itolizumab?

Itolizumab is a humanized recombinant immunoglobulin G1 (IgG1, a type of protein made in the laboratory to mimic natural antibodies) monoclonal antibody (a laboratory-made molecule designed to target specific cells). It works as a selective T-cell co-stimulation modulator by targeting the SRCR-D1 (Scavenger Receptor Cysteine-Rich) domain of CD6 (Cluster of Differentiation 6).

Medicinal Benefits:

Itolizumab injections treat inflammation in psoriasis and rheumatoid arthritis. Itolizumab is a humanized IgG1 (immunoglobulin G1), a monoclonal antibody that reduces cytokine production. Cytokine is a key substance in the inflammatory response. Recently, Itolizumab was also used in COVID-19 patients to manage severe lung inflammation and reduce breathing complications.

Warnings and Precautions:

• Severe rash, allergic reaction, or new symptoms of infection can be a sign to call for help.

• Known hypersensitivity to any component of Itolizumab.

• Monitor your vitals during treatment, as your physician recommends it to prevent serious complications.

• Exercise caution if you have HIV, active or latent tuberculosis, or hepatitis B or C.

• Alert your doctor if you receive dental or surgical procedures while you have Itolizumab.

• Itolizumab could affect fertility in both men and women.

• Consult your doctor if you are pregnant, plan to get pregnant, or are breastfeeding.

• Itolizumab is likely unsafe during pregnancy because it can pass through the placental barrier and lead to harm to the fetus.

• Breastfeeding is mostly unsafe during treatment with Itolizumab.

• Discuss with your healthcare provider whether to stop treatment or breastfeeding during this period.

• Use effective contraceptive methods during treatment and for at least five months after your last dose of Itolizumab.

Are you aware of how specific medications can affect different aspects of your health, like fertility or pregnancy? These details can be game-changers when deciding your treatment options.

Who Can Benefit from Itolizumab?

Itolizumab indications include restricted emergency treatment for patients with COVID-19 who are experiencing moderate to severe complications, including acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The main goal of Itolizumab is to help save patients with severe COVID-19. Additionally, Itolizumab is used to treat moderate to severe active chronic plaque psoriasis, a condition that causes dry, itchy, raised, scaly patches on the skin. Do you know someone struggling with psoriasis? Itolizumab is the game-changer they have been waiting for.

What Are the Contraindications of Itolizumab?

Itolizumab should not be used with alternative approved medications to treat plaque psoriasis or other biological agents to avoid the possibility and risk of developing an infection or elevating immunosuppression.

Mentioned below are the contraindications of Itolizumab:

• Patients who have a known history of severe hypersensitivity or anaphylactic reaction (severe, life-threatening allergic reaction) to the ingredients of Itolizumab.

• Patients have a known hypersensitivity or anaphylaxis to any murine proteins.

• Patients suffering from serious active infections, human immunodeficiency virus (HIV), and tuberculosis (bacterial lung infection).

• Low absolute lymphocyte or neutrophil count.

For Patients:

What Is the Composition of Itolizumab?

Itolizumab is an artificial anti-CD6 monoclonal antibody used by registered dermatologists and medical practitioners. Itolizumab injections contain a colorless and transparent solution.

The composition of each 5 mL (milliliter) vial of Itolizumab injection is mentioned below.

• Itolizumab 25 mg, r-DNA origin.

• Single-use vial.

• Intravenous, or IV, infusion.

How Does Itolizumab Work?

Itolizumab is a monoclonal antibody that targets and blocks a CD6 protein, which plays a role in the immune system. Thus, it helps reduce inflammation and control immune cells that may attack healthy tissues. This drug helps treat autoimmune diseases like psoriasis and prevents the immune system from causing damage to the body. By interfering with the CD6 protein, Itolizumab can reduce symptoms and improve patients’ overall quality of life, though it doesn't cure the conditions it treats.

Can Vaccinations Be Taken During Itolizumab Therapy?

There is no evidence of retaliation to vaccination with Itolizumab. Depending on the Itolizumab mechanism of action, it is believed that Itolizumab may hamper the effectiveness of live or attenuated vaccines. The gap between vaccination and starting treatment with Itolizumab should be in line with the latest guidelines on vaccinations. Special precautions should be considered while vaccinating newborns born to patients being treated with Itolizumab because of the potential for Itolizumab to cross the placental barrier.

What Are the Potential Side Effects of Itolizumab, and How Can They Be Managed?

The clinical trials of Itolizumab have not been conducted under hugely varying circumstances. Thus, the common Itolizumab reactions or undesirable effects of Itolizumab may not be predicted amongst a broader population of patients. It should also be noted that the most frequently reported adverse effect is an infusion-related reaction to Itolizumab.

Managing Itolizumab side effects usually involves talking with your healthcare provider. They can adjust the dosage or switch you to another treatment if necessary. Just keep your doctor in the loop about any side effects you are experiencing. That way, they can help guide you through it in the best way possible.

Nevertheless, at least one percent of patients treated with Itolizumab had experienced any undesirable effects mentioned below.

• Diarrhea.

• Vomiting.

• Toothache.

• Gastritis (inflammation of the stomach lining).

• Peripheral swelling (swelling in the arms or legs).

• Chest pain.

• Gastrointestinal inflammation (swelling of the digestive tract).

• Generalized pain.

• Abscess (pus-filled pocket under the skin or in tissues).

• Gastroenteritis (stomach flu, causing diarrhea and vomiting).

• Folliculitis (inflamed or infected hair follicles).

• Bacterial lymphadenitis (swollen lymph nodes due to bacteria).

• Tuberculosis of lymph nodes (bacterial infection in lymph nodes).

• Rhinitis (inflammation of the nasal passages).

• A tooth abscess (pus-filled infection near a tooth root).

• Oral herpes (cold sores or blisters around the mouth).

• Pyrexia (fever).

• Urinary tract infection.

• Dehydration (lack of enough water in the body).

• Hypertriglyceridemia (high levels of fats in the blood).

• Hepatic steatosis (fat buildup in the liver).

• Musculoskeletal pain (muscle, bone, or joint pain).

• Arthralgia.

• Backache.

• Pain in the limbs and extremities.

• Headache.

• Peripheral neuropathy (nerve damage causing tingling or numbness).

• Anxiety.

• Adjustment disorder (difficulty coping with life changes).

• Dysuria (painful or difficult urination).

• Adjustment disorder (difficulty coping with life changes).

• Dysuria (painful or difficult urination).

• Septic arthritis (a joint infection causing pain and swelling).

• Exfoliative dermatitis (widespread peeling or flaking skin).

• Erythrodermic psoriasis (severe skin redness and scaling).

• Pruritus (itchy skin).

• Upper respiratory tract infection.

• Rhinorrhea (runny nose).

• Cough.

• Oropharyngeal pain (sore throat or mouth discomfort).

• Keloid scar (thick, raised scar after healing).

What Are the Dosage and Administration Guidelines?

When dealing with plaque psoriasis or cytokine release syndrome, the first dose is usually 1.6 mg per 2.20462 pounds, given as an IV (intravenous) infusion. For plaque psoriasis, the patient will get 1.6 mg per 2.20462 pounds, every two weeks for the first 12 weeks. After that, it switches to 1.6 mg per 2.20462 every four weeks until 24 weeks. Around 50 ml will be given in the first hour, then the rest of the dose will be given over the next hour.

As for cytokine release syndrome, the first infusion of 1.6 mg per 2.20462 should start at 25 ml per hour for the first hour. If everything is tolerated well, they will increase the rate to 50 ml per hour for five to six hours. Itolizumab comes in a single-dose vial for injection, meant for IV use, with each vial containing 100 mg of Itolizumab (rDNA origin).

What Happens During an Overdose of Itolizumab?

There has not been any evidence of dose-limiting toxicities in any of the clinical trials done with Itolizumab. There have not been any adverse effects in individuals from clinical trials who received a dose of Itolizumab of up to 23.2 mg (milligrams) along with a cumulative dose of 50 mg in the initial week of therapy. In case of any overdose, management should be instituted as soon as possible based on the manifesting symptoms.

Storage: Itolizumab should be stored as follows:

• In the refrigerator.

• Away from light.

• In the original container.

Safety Advice:

• Alcohol: Avoid alcohol due to the potential for increased dizziness.

• Pregnancy: Not recommended unless the benefits are more than the risk.

• Breastfeeding: Use caution as it is unclear if Itolizac passes into breast milk.

• Driving: Stay away from driving or operating machinery if you experience dizziness.

• Liver and Kidney: Use caution in patients with liver or kidney impairment; dose adjustments may be needed.

• Children: Not recommended for children or adolescents under 18 years old.

For Doctors:

What Is the Mechanism of Action of Itolizumab?

Itolizumab is an advanced anti-CD6 (cluster of differentiation 6) antibody that targets a specific domain, SRCS-1 (scavenger receptor cysteine-rich domain 1), on CD6. It reduces inflammation. It blocks TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin-6), and IFN-γ (interferon-gamma), which are pro-inflammatory signals, without lowering T-cells. Itolizumab inhibits T-cell activation and adhesion. It helps to control autoimmune conditions like psoriasis and rheumatoid arthritis.

Itolizumab's mechanism of action prevents cytokine storms by downregulating inflammatory pathways. Unlike its parent antibody, IOR-T1 (murine monoclonal antibody), Itolizumab is safer, less immunogenic, and more effective. The ability of Itolizumab to suppress the immune system's overactive response makes it particularly useful for autoimmune conditions where the body turns on itself.

What Is the Principle That Itolizumab Works On?

CRS (cytokine release syndrome) is characterized by an overproduction of cytokines, such as TNF-α, IL-6, and IFN-γ, which leads to an exaggerated inflammatory response. It has also been linked to many dangerous complications that have been described in various diseases, including autoimmune diseases. Itolizumab changes the immune response by T-cell activation and suppressing pro-inflammatory cytokines.

What Are the Pharmacodynamic Properties of Itolizumab?

Itolizumab is an isotope that links with the CD6 domain 1. The antigen of CD6 leukocyte differentiation is mainly seen in most peripheral blood CD3+ T cells. CD6 is a co-stimulatory molecule that activates cells in peripheral blood T cells. It has been established in various preclinical studies of T cells that the antibody blocks MAPK or intracellular mitogen-activated protein kinase, as well as STAT-3 or signal transducer and activator of transcription-3. A span of in vitro as well as in vivo studies in mice about the pharmacological properties of Itolizumab has exemplified the reaction with human CD6 as well as the therapeutic accuracy of Itolizumab in SCID-Hu or severe combined immunodeficiency disease-human xenograft model of psoriasis.

What Are the Pharmacokinetic Properties of Itolizumab?

The pharmacokinetic properties of Itolizumab are as follows:

Dose and Route of Administration:

• 0.4 mg per kilogram (milligrams per kilogram of body weight) to 1.6 mg per kilogram was given.

• The route was intravenous (IV).

• Serum drug levels were assayed using the ELISA (enzyme-linked immunosorbent assay) technique.

Dose-Dependent Findings: A dose-dependent and linear relationship was seen in multiple pharmacokinetic parameters. The Cmax (maximum drug concentration) and AUC (area under the concentration-time curve) were dose-proportional. Itolizumab dosage regimens consisted of giving the following once a week, every other week, or every four weeks.:

1. 0.4 mg per kilogram.

2. 1.6 mg per kilogram.

Frequency and Concentration Dynamics:

• With increased frequency, the drug accumulation increased.

• The decreased frequency caused minimal clearance of the Itolizumab drug.

• Half-Life (t½): The half-life (t½) of Itolizumab after the last dose was between 11.72 and 18.51 days, depending on the Itolizumab dosage and frequency combination.

• The pharmacokinetics of Itolizumab exhibit dose-dependent, predictable behavior with varying concentration and clearance based on the dosing schedules, thereby supporting its use in managing psoriasis.

What Are the Clinical Trials Done for the Treatment of Psoriasis With Itolizumab?

Itolizumab, a humanized anti-CD6 monoclonal antibody, has shown promise as a novel treatment for chronic plaque psoriasis. The therapy is well-tolerated, with comparable adverse event rates across all groups and no higher infection risk than placebo. Infusion reactions were the most common Itolizumab side effects. Beyond psoriasis, Itolizumab shows potential for other autoimmune conditions like multiple sclerosis, rheumatoid arthritis, and Sjögren's syndrome.

What Are the Limitations of Use of Itolizumab?

Patients should be screened using the Mantoux test and chest X-rays for active or latent tuberculosis. The healthcare provider should be alert when administering Itolizumab to patients with hepatitis C and B infection, patients who have received or are still receiving chronic steroid therapy, and patients who have received or are still receiving chronic steroid therapy. The efficacy and safety of Itolizumab have not been examined in the cases below.

• Pediatric patients.

• Patients less than 18 years of age.

• Patients with renal insufficiency.

• Patients with hepatic impairment.

• Pregnant patients.

• Lactating patients.

Itolizumab Drug Interactions:

Itolizumab with other biologicals is not recommended due to a lack of studies on such interactions. Additionally, its impact on vaccinations has not been studied, and live or attenuated vaccines should not be administered alongside Itolizumab as it may reduce vaccine efficacy.

Uses in Specific Population:

Pregnancy: Itolizumab, a monoclonal antibody or IgG antibody, may potentially cross the placental barrier during pregnancy. There are no details or records if Itolizumab can lead to any harm to the fetus in case it is administered to a pregnant patient. There are no established results of any reproductive infertility or reduction in reproductive capacity.

Lactating Females: There is no data to confirm the presence or absence of Itolizumab in human milk, and there is no proof that It was absorbed after digestion. However, lactating females' healthcare providers can decide whether to proceed with Itolizumab therapy.

Itolizumab vs. Other Similar Treatments:

Itolizumab:

• Monoclonal antibody targets CD6 in the immune system.

• Used for conditions like plaque psoriasis and cytokine release syndrome.

• Specifically targets the immune system's overreaction.

• It may have fewer side effects for some patients because its action is more targeted.

TNF Inhibitors (e.g., Infliximab, Adalimumab):

• They target and block TNF-alpha, a protein that’s involved in inflammation.

• Used for rheumatoid arthritis, psoriasis, and Crohn’s disease.

• They affect the immune system more broadly, and that might lead to more side effects than Itolizumab.

• Depending on the person, some patients may do better on Itolizumab than TNF inhibitors.

Interleukin Inhibitors (e.g., Ustekinumab):

• They target specific interleukins involved in inflammation, like IL-12 and IL-23.

• Often used for psoriasis and Crohn’s disease.

• They offer targeted therapy rather than corticosteroids.

• Work in a targeted way to treat the cause of the disease.

Comparison:

• Itolizumab has fewer side effects for some patients.

• TNF and interleukin inhibitors both target different pathways in inflammation, which may help a wide range of conditions, but sometimes with more side effects.

• Choosing a treatment often depends on how a person responds, how many side effects they can tolerate, and other health issues they might have. So, personalized care is critical in figuring out what is best.

Conclusion:

In conclusion, Itolizumab can be helpful in psoriasis, lupus nephritis, and even COVID-19. It works by targeting CD6 directly, which makes it stand out from other treatments. People with diseases like tuberculosis or HIV should be careful, I guess. So, you should keep in touch with your doctor when you are on it. Although it is showing promise already, there is still a lot of research to be done, and we still do not know how it will all turn out.

Key Takeaway/A Note from Icliniq

Itolizumab helps with severe conditions like psoriasis and lupus nephritis and even helps with COVID-19. However, it is important to stay cautious with its use, especially if you have any other health issues like tuberculosis or HIV. Do not be afraid to reach out to iCliniq. Getting expert advice makes all the difference. Health is a team effort for doctors, family, and friends. They all play their part. Take care of yourself and ensure you are well-supported through any treatment you choose!